NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Review of NICE Technology Appraisal guidance no. 67, on the use of oseltamivir, amantadine and zanamivir for the prophylaxis of influenza

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Manufacturers/sponsors Alliance Pharmaceuticals Ltd (amantadine) GlaxoSmithKline (zanamivir) Roche Products Ltd (oseltamivir) Patient/carer groups Action Heart African HIV Policy Network (AHPN) Age Concern England Asthma UK Black and Ethnic Minority Diabetes Association British Cardiac Patients Association British Cardiovascular Society British Kidney Patient Association British Lung Foundation Counsel and Care Diabetes UK HEART UK Help the Aged Kidney Alliance NAM Publications National Kidney Federation (UK) Specialised Healthcare Alliance The Terrence Higgins Trust UK Coalition of People Living with HIV and AIDS UK Public Health Association 	 General Age Concern Cymru Board of Community Health Councils in Wales British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency (MHRA) National Public Health Service for Wales NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium Welsh Kidney Patients Association Comparator manufacturers (none) Relevant research groups British Society for Cardiovascular Research Institute for Ageing and Health Juvenile Diabetes Research Foundation Policy Research Institute on Ageing and Ethnicity (PRIAE) Research Institute for the care of the Elderly
 Professional groups British Association for Service to the 	Assessment team

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the review of NICE Technology Appraisal guidance no. 67, on the use of oseltamivir, amantadine and zanamivir for the prophylaxis of influenza

Consultees	Commentators (no right to submit or appeal)
 Elderly British Geriatrics Society British Heart Foundation British Paediatric Respiratory Society British Thoracic Society Faculty of Public Health Medicine General Practice Airways Group (GPIAG) Health Protection Agency National Heart Forum (UK) National Pharmacy Association (NPA) Primary Care Cardiovascular Society Royal College of General Practitioners Royal College of Paediatrics and Child Health Royal College of Paediatrics and Child Health Royal College of Physicians Royal College of Physicians Royal Institute of Public Health Royal Society of Medicine – Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association 	 National Coordinating Centre for Health Technology Assessment School of Health & Related Research Sheffield <u>Associated Guideline Groups</u> (none) <u>Associated Public Health Groups</u> (none)

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the review of NICE Technology Appraisal guidance no. 67, on the use of oseltamivir, amantadine and zanamivir for the prophylaxis of influenza

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the review of NICE Technology Appraisal guidance no. 67, on the use of oseltamivir, amantadine and zanamivir for the prophylaxis of influenza